Literature DB >> 17544563

Use of oxytocin to prevent haemorrhage at caesarean section--a survey of practice in the United Kingdom.

Lilantha Wedisinghe1, Maureen Macleod, Deirdre J Murphy.   

Abstract

OBJECTIVE: To establish the views and current practice of obstetricians and anaesthetists with regard to the use of oxytocin to prevent haemorrhage at caesarean section. STUDY
DESIGN: A national survey of all lead consultant obstetricians and anaesthetists for the labour ward in the United Kingdom. A postal questionnaire was sent to all clinicians with one subsequent reminder to non-responders. The use of oxytocin bolus and infusion, perceived side effects of intravenous oxytocin, estimated blood loss at caesarean section, and willingness to participate in a future clinical trial were explored.
RESULTS: The response rate was 84% (365 respondents). A slow bolus of 5 IU oxytocin was the preferred approach of obstetricians and anaesthetists (153, 86% and 171, 92%, respectively). Oxytocin infusions were used routinely by 72 clinicians (20%) with selective use for particular clinical circumstances by 289 (80%). Most clinicians used either 30 IU (158, 43%) or 40 IU (192, 53%) infusions over 4h, with a total of 38 different regimens. The perceived risk of side effects with an oxytocin infusion was low. Estimated "average" blood loss varied (150-1,500 ml) with 56 clinicians (17%) and 93 (28%) reporting a >20% risk of postpartum haemorrhage for elective and emergency caesarean sections, respectively.
CONCLUSION: There is wide variation in the use of oxytocin at caesarean section reflecting limited research in this area. Excess haemorrhage is considered to occur frequently and the perceived risk of oxytocin bolus and infusion is low. Further research is required addressing the optimal use of oxytocic agents at caesarean section.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17544563     DOI: 10.1016/j.ejogrb.2007.04.007

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  6 in total

1.  Refusal of blood transfusion by Jehovah's Witness women: a survey of current management in obstetric and gynaecological practice in the U.K.

Authors:  Sahana Gupta; Joseph Onwude; Roberto Stasi; Isaac Manyonda
Journal:  Blood Transfus       Date:  2012-07-04       Impact factor: 3.443

2.  Oxytocin bolus versus oxytocin bolus and infusion for control of blood loss at elective caesarean section: double blind, placebo controlled, randomised trial.

Authors:  Sharon R Sheehan; Alan A Montgomery; Michael Carey; Fionnuala M McAuliffe; Maeve Eogan; Ronan Gleeson; Michael Geary; Deirdre J Murphy
Journal:  BMJ       Date:  2011-08-01

3.  Single-cell mechanics and calcium signalling in organotypic slices of human myometrium.

Authors:  Fiona C Loftus; Magnus J E Richardson; Anatoly Shmygol
Journal:  J Biomech       Date:  2015-02-08       Impact factor: 2.712

4.  Study protocol. ECSSIT - Elective Caesarean Section Syntocinon Infusion Trial. A multi-centre randomised controlled trial of oxytocin (Syntocinon) 5 IU bolus and placebo infusion versus oxytocin 5 IU bolus and 40 IU infusion for the control of blood loss at elective caesarean section.

Authors:  Deirdre J Murphy; Michael Carey; Alan A Montgomery; Sharon R Sheehan
Journal:  BMC Pregnancy Childbirth       Date:  2009-08-24       Impact factor: 3.007

5.  A comparison of oxytocin and carboprost tromethamine in the prevention of postpartum hemorrhage in high-risk patients undergoing cesarean delivery.

Authors:  Jing Bai; Qian Sun; Hui Zhai
Journal:  Exp Ther Med       Date:  2013-11-01       Impact factor: 2.447

6.  The ED50 and ED95 of oxytocin infusion rate for maintaining uterine tone during elective caesarean delivery: a dose-finding study.

Authors:  Xiao Wei Qian; Dan M Drzymalski; Chang Cheng Lv; Fei He Guo; Lu Yang Wang; Xin Zhong Chen
Journal:  BMC Pregnancy Childbirth       Date:  2019-12-31       Impact factor: 3.007

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.